Sammy Farah, Turnstone Biologics CEO

Turn­stone charts $75M IPO for TIL cell ther­a­pies in drum­roll of biotech IPOs this month

Turn­stone Bi­o­log­ics plans to list on the Nas­daq in a $75 mil­lion raise short­ly af­ter a trio of biotechs — Apogee Ther­a­peu­tics, Sagimet Bio­sciences and 60 De­grees Phar­ma­ceu­ti­cals — went pub­lic fol­low­ing a stretch of in­ac­tiv­i­ty for the be­lea­guered sec­tor.

The sol­id tu­mor cell ther­a­py biotech hopes to mark a turn­around af­ter los­ing key deals with Ab­b­Vie in 2021 and Take­da in 2022 and en­act­ing lay­offs last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.